Video

Educated Patient® Leukemia and Lymphoma Summit: October 27, 2020

Author(s):

CURE Media Group

View the entire CURE® Educated Patient® Leukemia & Lymphoma Summit. A virtual event seeking to educate, inform and challenge the thinking of patients with leukemia and lymphoma.

View the entire CURE® Educated Patient® Leukemia & Lymphoma Summit. A virtual event seeking to educate, inform and challenge the thinking of patients with leukemia and lymphoma.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Clinical Trial Evaluating Monjuvi in Lymphoma Gives Lasting Responses
Mark Daniels, an 83-year-old veteran and former fighter pilot, was shocked by his lymphoma diagnosis because he maintained exceptional physical fitness.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Image of two doctors and text.
Imiage of two doctors with text.
Related Content
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer: © stock.adobe.com.
July 24th 2025

Key Immune Cells Linked to Better Kidney Cancer Outcomes

Ashley Chan
PD-1 treatment may help by shifting certain immune cells to fight diseases like kidney cancer; higher CD163-positive TAMs are linked to better outcomes.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes: © stock.adobe.com.
July 22nd 2025

Clinical Trial Confirms Keytruda and Lenvima Benefit in Kidney Cancer

Russ Conroy
Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe subtypes.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of kidney.
July 20th 2025

Welireg Improves Quality-Adjusted Survival Time in Advanced RCC

Russ Conroy
Welireg improved quality-adjusted survival time versus Afinitor in advanced renal cell carcinoma, extending progression-free survival and reducing side effects.
Researchers are exploring the use of CAR T-cell therapy in clear cell renal cell carcinoma, a type of kidney cancer: © stock.adobe.com.
July 20th 2025

Dual-Targeting CAR T Therapy Shows Potential in Advanced Kidney Cancer

Ashley Chan
Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell carcinoma, a type of kidney cancer.